Description

BridgeBio Pharma’s Attruby Breakthrough — Real-World Data Sharpens The Pfizer Battle!

BridgeBio Pharma reported strong commercial performance in the first quarter of 2026, primarily driven by its ATTR-CM franchise, Attruby (acoramidis), which generated $180.6 million in U.S. net product revenue—a 24% increase from the prior quarter and a 392% year-over-year increase. This growth is attributed to increased new patient starts, expanded sales efforts, and gains in first-line market share. Attruby’s near-complete TTR stabilization profile and emerging real-world evidence (RWE) data supporting its clinical differentiation versus tafamidis underpin the sales momentum. Notably, recent RWE studies demonstrate reductions in mortality risk, diuretic intensification, and acute kidney injury incidence with Attruby, further supporting its differentiated profile. The company highlighted that Attruby is gaining traction as the second brand by volume in its treatment category despite strong competition from Pfizer. BridgeBio continues to prepare for upcoming product launches including BBP-418 for LGMD2I, Encaleret for autosomal dominant hypocalcemia type 1 (ADH1), and Infigratinib for achondroplasia.